# Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

> **NCT00494533** · PHASE4 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Remodulin (treprostinil sodium)

## Key facts

- **NCT ID:** NCT00494533
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Safety issues related to outpatient intravenous infusion in India
- **Last updated:** 2014-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494533, "Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00494533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*